Company profile
Axsome Therapeutics, Inc.
NASDAQ: AXSM · Healthcare · Biotechnology
#193 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
59CFH 56DQ 57GM 65SS 77
v0.1 · 65/100 weight · provisional
↑ market scale, 3-yr revenue growth · ↓ return on equity, growth stability
Methodology →Revenue TTM
$708.2M
Rev growth YoY (TTM)
+63.9%
Net income (FY)
-$183.2M
Employees
1,220
as of 2026-08-05
Market cap
$10.9B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$638.5M$638.5M2025
Net income-$183.2M-$183.2M2025
Operating income-$166.8M-$166.8M2025
Total assets$689.8M$689.8M2025
Liabilities$601.5M$601.5M2025
Equity$88.3M$88.3M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product100%
By geography
UNITED STATES99%
Non-US1%
The read
What is Axsome Therapeutics, Inc.’s revenue?
Axsome Therapeutics, Inc. booked $638.5M in FY2025 revenue, growing 66% year over year — faster than most Healthcare companies we track, at a -28.7% net margin.
Peers · Healthcare
Cresco Labs Inc.37DDoximity, Inc.73B10x Genomics, Inc.67BTG Therapeutics, Inc.72BOPKO Health, Inc.74BInsmed Incorporated66BNeighbors
New York →Key facts
CEOHerriot Tabuteau
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York City, NY
ExchangeNASDAQ: AXSM
Employees1,220
IPO date2015-11-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.